Article Published in Managed Care Highlights the Benefits of Diabetes Medication Delivery Devices, Including Valeritas’ V-Go® Device

BRIDGEWATER, N.J., March 30, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced the publication of an article that highlights the benefit of diabetes medication delivery devices, including Valeritas’ V-Go^® Device, for improving treatment outcomes for patients with diabetes. The review article, “Novel Devices for Delivering Diabetes Medications: Their Value and Some Coverage Considerations,” was published in the March, 2017 issue of Managed Care, vol. 6 (3): 42-45.

The article highlights a number of diabetes medication delivery devices and their impact on treatment outcomes and the healthcare system compared to standard delivery approaches (syringes and pens) and formulations (sub-cutaneous and oral). The author, Bruce W. Sherman, M.D., concluded that, “plan sponsors will benefit from consideration of … drug-delivery devices as part of an expanded approach to effective diabetes management. Inclusion of these offerings as part of the pharmacy benefit may improve adherence because PBMs [pharmacy benefit managers] traditionally focus on medication adherence and may also lower acquisition costs for both patients and plan sponsors.”

“Despite significant resources directed toward diabetes care, including a large number of drug products and managed care programs to improve patient access to medicines, many patients with diabetes still do not reach their treatment goals,” said John Timberlake, President and Chief Executive Officer of Valeritas. “This article reviews how diabetes medication delivery devices, including V-Go Wearable Insulin Delivery Device, improved treatment outcomes and reduced both short-term pharmacy costs and longer-term healthcare costs. We have worked diligently to demonstrate the value of V-Go to patients, their physicians and payers through the execution of numerous clinical studies and we are gratified by the recognition of that work. Diabetes is a costly chronic illness and we will continue to work with payers to adopt V-Go on their pharmacy formulary which will simplify and broaden access to V-Go to improve A1c outcomes at a lower cost to the employers and their insured population.” 

Valeritas provided an unrestricted educational grant for preparation of this manuscript.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go^® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Forward Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go^® Disposable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.

Investor Contacts:
Nick Laudico / Robert Flamm, Ph.D.
The Ruth Group
(646)536-7030 / 7017
[email protected]

Or

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
[email protected]

Media Contact:
Kirsten Thomas
The Ruth Group
(508)280-6592
[email protected]